Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 2
2017 5
2018 6
2019 9
2020 6
2021 10
2022 4
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade.
Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, Yates KB, Lako A, Felt K, Naik GS, Manos M, Gjini E, Kuchroo JR, Ishizuka JJ, Collier JL, Griffin GK, Maleri S, Comstock DE, Weiss SA, Brown FD, Panda A, Zimmer MD, Manguso RT, Hodi FS, Rodig SJ, Sharpe AH, Haining WN. Miller BC, et al. Among authors: weiss sa. Nat Immunol. 2019 Mar;20(3):326-336. doi: 10.1038/s41590-019-0312-6. Epub 2019 Feb 18. Nat Immunol. 2019. PMID: 30778252 Free PMC article.
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target.
Manguso RT, Pope HW, Zimmer MD, Brown FD, Yates KB, Miller BC, Collins NB, Bi K, LaFleur MW, Juneja VR, Weiss SA, Lo J, Fisher DE, Miao D, Van Allen E, Root DE, Sharpe AH, Doench JG, Haining WN. Manguso RT, et al. Among authors: weiss sa. Nature. 2017 Jul 27;547(7664):413-418. doi: 10.1038/nature23270. Epub 2017 Jul 19. Nature. 2017. PMID: 28723893 Free PMC article.
Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance.
Krykbaeva I, Bridges K, Damsky W, Pizzurro GA, Alexander AF, McGeary MK, Park K, Muthusamy V, Eyles J, Luheshi N, Turner N, Weiss SA, Olino K, Kaech SM, Kluger HM, Miller-Jensen K, Bosenberg M. Krykbaeva I, et al. Among authors: weiss sa. Cancer Immunol Res. 2023 Oct 4;11(10):1332-1350. doi: 10.1158/2326-6066.CIR-22-0699. Cancer Immunol Res. 2023. PMID: 37478171
A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better.
Djureinovic D, Weiss SA, Krykbaeva I, Qu R, Vathiotis I, Moutafi M, Zhang L, Perdigoto AL, Wei W, Anderson G, Damsky W, Hurwitz M, Johnson B, Schoenfeld D, Mahajan A, Hsu F, Miller-Jensen K, Kluger Y, Sznol M, Kaech SM, Bosenberg M, Jilaveanu LB, Kluger HM. Djureinovic D, et al. Among authors: weiss sa. Mol Cancer. 2023 Nov 14;22(1):182. doi: 10.1186/s12943-023-01884-x. Mol Cancer. 2023. PMID: 37964379 Free PMC article.
Immunotherapy of Melanoma: Facts and Hopes.
Weiss SA, Wolchok JD, Sznol M. Weiss SA, et al. Clin Cancer Res. 2019 Sep 1;25(17):5191-5201. doi: 10.1158/1078-0432.CCR-18-1550. Epub 2019 Mar 28. Clin Cancer Res. 2019. PMID: 30923036 Free PMC article. Review.
Resistance mechanisms to checkpoint inhibitors.
Weiss SA, Sznol M. Weiss SA, et al. Curr Opin Immunol. 2021 Apr;69:47-55. doi: 10.1016/j.coi.2021.02.001. Epub 2021 Mar 3. Curr Opin Immunol. 2021. PMID: 33676271 Review.
A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy.
Weiss SA, Sznol M, Shaheen M, Berciano-Guerrero MÁ, Couselo EM, Rodríguez-Abreu D, Boni V, Schuchter LM, Gonzalez-Cao M, Arance A, Wei W, Ganti AK, Hauke RJ, Berrocal A, Iannotti NO, Hsu FJ, Kluger HM. Weiss SA, et al. Clin Cancer Res. 2024 Jan 5;30(1):74-81. doi: 10.1158/1078-0432.CCR-23-0475. Clin Cancer Res. 2024. PMID: 37535056 Free PMC article. Clinical Trial.
45 results